scholarly journals Differentiating between Glioblastoma and Primary CNS Lymphoma Using Combined Whole-tumor Histogram Analysis of the Normalized Cerebral Blood Volume and the Apparent Diffusion Coefficient

2019 ◽  
Vol 18 (1) ◽  
pp. 53-61 ◽  
Author(s):  
Shixing Bao ◽  
Yoshiyuki Watanabe ◽  
Hiroto Takahashi ◽  
Hisashi Tanaka ◽  
Atsuko Arisawa ◽  
...  
2020 ◽  
Vol 13 (12) ◽  
Author(s):  
Nguyen Duy Hung ◽  
Nguyen Minh Duc ◽  
Ta Hong Nhung ◽  
Le Thanh Dung ◽  
Bui Van Giang ◽  
...  

Background: Central nervous system (CNS) lymphoma presents as the dense infiltration of tumor cells in the perivascular space and blood-brain barrier disruption, on histopathological examination. The Ki-67 expression has been significantly correlated with tumor proliferation and is considered to be a prognostic factor. Objectives: This study aimed at analyzing the correlations among the apparent diffusion coefficient (ADC), the relative cerebral blood volume (rCBV), and the Ki-67 proliferation index in CNS lymphoma. Methods: From August 2019 to March 2020, 26 patients (14 men and 12 women) who underwent biopsy or surgery and were histologically confirmed as CNS lymphoma were included in this retrospective study. Diffusion and perfusion acquisitions were performed in 26 and 10 examinations, respectively. The Ki-67 proliferation index was available for all cases. Results: The mean tADC, rADC, and rCBV values were 0.61 ± 0.12 × 10-3 mm2/s, 0.73 ± 0.14, and 1.1 ± 0.32, respectively. Negative correlations were identified between both tADC and rADC and the Ki-67 proliferation index (r = -0.656, P < 0.01 and r = -0.540, P < 0.01, respectively). No significant correlations were found between rCBV values and the Ki-67 proliferation index, between rCBV and rADC, or between rCBV and tADC. Conclusions: tADC and rADC values can be used as noninvasive indicators to predict cell proliferation in CNS lymphoma.


Radiology ◽  
2009 ◽  
Vol 253 (2) ◽  
pp. 505-512 ◽  
Author(s):  
Gisele Brasil Caseiras ◽  
Olga Ciccarelli ◽  
Daniel R. Altmann ◽  
Christopher E. Benton ◽  
Daniel J. Tozer ◽  
...  

2019 ◽  
Vol 8 (11) ◽  
pp. 2007
Author(s):  
Cuccarini ◽  
Aquino ◽  
Gioppo ◽  
Anghileri ◽  
Pellegatta ◽  
...  

Evaluating changes induced by immunotherapies (IT) on conventional magnetic resonance imaging (MRI) is difficult because those treatments may produce inflammatory responses. To explore the potential contribution of advanced MRI to distinguish pseudoprogression (PsP) and true tumor progression (TTP), and to identify patients obtaining therapeutic benefit from IT, we examined aMRI findings in newly diagnosed glioblastoma treated with dendritic cell IT added to standard treatment. We analyzed longitudinal MRIs obtained in 22 patients enrolled in the EUDRACT N° 2008-005035-15 trial. According to RANO criteria, we observed 18 TTP and 8 PsP. Comparing MRI performed at the time of TTP/PsP with the previous exam performed two months before, a difference in cerebral blood volume ΔrCBVmax ≥ 0.47 distinguished TTP from PsP with a sensitivity of 67% and specificity of 75% (p = 0.004). A decrease in minimal apparent diffusion coefficient rADCmin (1.15 vs. 1.01, p = 0.003) was observed after four vaccinations only in patients with a persistent increase of natural killer cells (response effectors during IT) in peripheral blood. Basal rADCmin > 1 was independent predictor of longer progression free (16.1 vs. 9 months, p = 0.0001) and overall survival (32.8 vs. 17.5 months, p = 0.0005). In conclusion, rADC predicted response to immunotherapy and survival; Apparent Diffusion Coefficient (ADC) and Cerebral Blood Volume (CBV) modifications over time help differentiating PsP from TTP at onset.


Sign in / Sign up

Export Citation Format

Share Document